Dabur reported a 6.18% fall in net profits at Rs.341 crore for the Jun-20 quarter due to lower operating revenues. Overall revenues from operations for the quarter under review were down 12.90% at Rs.1980 crore. Dabur admitted that the COVID pandemic had brought business to a standstill. That had led to the sharp fall in top-line.

As a strategy, Dabur had introduced a record number of new products and variants largely anchored on consumer needs for health, immunity and hygiene. In fact, Dabur recorded sales of Rs.100 crore from new products. Many of Dabur’s new products are in the healthcare space. Dabur will also look to strengthen its position as a dominant player in the Ayurvedic Healthcare and Hygiene products markets, which is a niche dominance for Dabur.